5-MAPB Stats & Data

5-MAPB emerged on the designer drug market around 2010 as part of the wave of novel benzofuran entactogens developed as alternatives to controlled substances like MDMA. The compound was first formally identified and documented by researchers in 2013, with the initial scientific literature describing its properties published in 2014. Following its appearance on the recreational market and subsequent scheduling in multiple countries, 5-MAPB has attracted interest for potential therapeutic applications. The compound has been patented by Tactogen, a pharmaceutical company exploring entactogens as candidates for development into regulated medicines.

The toxicity and long-term health effects of recreational 5-MAPB use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because 5-MAPB has very little history of human usage. Anecdotal evidence from people who have tried 5-MAPB within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). 5-MAPB's notable agonism at the serotonin-2b (5-HT2b) receptor (which has been associated with cardiovalvulopathy) suggests that it would be cardiotoxic with long-term use, as seen in other 5-HT2B agonists such as fenfluramine and MDMA. It is strongly recommended that one use harm reduction practices when using this drug.

Effects aggregated from 23 experience reports (8 single-substance Erowid + 15 Bluelight)

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Rows resting on fewer than 20 reports show a count (“3 of 7”) instead of a bar. Why 20?

Also reported in combinations. In the 13 5-MAPB reports where another drug was taken too, 0 mention hospital, emergency services or an overdose, 0 a seizure and 1 psychosis (too few reports for percentages). In the 8 single-substance reports: 0, 0 and 0. These are not in the figures above: they cannot be put down to 5-MAPB alone, and a mention is not always something that happened to the writer.

From 43 of 45 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

Most co-occurring substances, as a share of all 21 reports filed under 5-MAPB; whiskers are 95% intervals

Most common forms and preparations, as a share of the 11 reports that give one

Too few reports for bars: these forms come from 11 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

• Powder / Crystals 7 of 11
• Capsule 4 of 11

Redosing behavior across 13 reports